Table 3.
Laboratory findings before and after ezetimibe monotherapy and combined therapy
| Monotherapy | (n = 71) | Combined therapy | (n = 20) | |
|---|---|---|---|---|
| Parameters | Pre | Post 6M | Pre | Post 6M |
| Body mass index (kg/m2) | 28.2 ± 3.7 | 28.0 ± 3.8 | 27.2 ± 2.0 | 25.9 ± 1.6* |
| Waist circumference (cm) | 94.6 ± 8.2 | 92.8 ± 8.6*** | 91.0 ± 5.6 | 88.3 ± 5.3** |
| Systolic blood pressure (mmHg) | 130.1 ± 14.6 | 128.8 ± 13.2* | 125.6 ± 13.8 | 121.8 ± 11.2 |
| Diastolic blood pressure (mmHg) | 77.3 ± 9.5 | 75.9 ± 10.6* | 71.7 ± 8.2 | 69.5 ± 7.7 |
| Total cholesterol (mg/dl) | 237.9 ± 35.9 | 212.0 ± 33.0*** | 224.7 ± 27.8 | 192.2 ± 36.1* |
| LDL-cholesterol (mg/dl) | 151.3 ± 28.6 | 132.4 ± 28.6*** | 132.1 ± 26.8 | 107.8 ± 30.5* |
| HDL-cholesterol (mg/dl) | 51.9 ± 9.9 | 55.1 ± 9.4*** | 50.8 ± 11.9 | 53.3 ± 11.5*** |
| Non HDL-cholesterol (mg/dl) | 184.9 ± 31.7 | 155.6 ± 32.5*** | 174.6 ± 25.8 | 141.8 ± 32.2** |
| Triglycerides+ (mg/dl) | 157.5 | 129.2*** | 210.9 | 155.3*** |
| RLP-cholesterol+ (mg/dl) | 6.3 | 4.7** | 8.2 | 4.7*** |
| Free fatty acid+ (mEq/l) | 435.9 | 505.6* | 435.4 | 429.7 |
| Plasma glucose (mg/dl) | 105.1 ± 27.9 | 102.6 ± 26.4* | 109.3 ± 21.7 | 105.1 ± 15.9 |
| Insulin+ (μU/ml) | 12.1 | 9.6** | 11.7 | 11.4 |
| HOMA index+ | 3.0 | 2.4** | 3.2 | 2.9 |
| hsCRP+ (mg/dl) | 807.0 | 883.7* | 686.1 | 879.6* |
| Aldosterone (pg/dl)+ | 86.9 | 92.9* | 101.6 | 110.8 |
| HGF (ng/ml) | 0.33 ± 0.07 | 0.31 ± 0.04* | 0.31 ± 0.03 | 0.30 ± 0.02 |
| Adiponectine (μg/ml)+ | 2.51 | 2.56 | 2.49 | 2.47 |
| EPA/AA+ | 0.29 | 0.28 | 0.39 | 0.40 |
*: p < 0.05, **: p < 0.01, ***: p < 0.001.
Data are means (SD), geometric mean and range. *: These variables are shown in the original scale after analysis using log (natural)-transformed values.
Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to arachidonic acid.